SYNOPSIS Three patients with Christmas disease whose plasma was shown to have a prolonged one-stage prothrombin time with ox brain thromboplastin have been investigated. These patients have an inhibitor for the reaction between factor X, factor VII, and ox brain extract. The abnormal constituent responsible for this inhibitor appears to be factor IX whuch is functionally inactive but antigenically indistinguishable from normal factor IX. It is proposed that patients might be classified into haemophilia B+ for patients with this defect (Christmas disease+) and haemophilia B-(Christmas disease-) for patients who have classical Christmas disease.
In a previous communication, the plasma of an 18-month-old child with factor IX deficiency was shown to have a slightly prolonged one-stage prothrombin time with human or rabbit brain thromboplastin, and a grossly abnormal prothrombin time using ox or horse brain as thromboplastin (Kidd, Denson, and Biggs, 1963) . Since this time, plasma samples from two further patients with factor IX deficiency have also been shown to have grossly prolonged clotting times in the presence of ox brain. Though the phenomenon seems to have no physiological significance the abnormality is inheritted (Hougie, and Twomey, 1967) and it was thought that it might be associated with an abnormal factor IX molecule.
METHODS
PLASMA SAMPLES Blood was collected into one tenth volume of 3-8 % sodium citrate and the plasma separated by centrifuging at 3,000 rpm for 15 minutes. OX BRAIN THROMBOPLASTIN Ox brain was collected freshly from the slaughter house and the superficial membranes were removed. It was then extracted with six to seven changes of acetone and the dried powder stored in a vacuum dessicator. For use, 0-5 g was suspended in 10 ml of saline and heated at 50°C for 20 minutes. HUMAN Received for publication 20 July 1967. 160 BOVINE FACTOR VII, FACTOR X, AND FACTOR IX These were prepared by column chromatography on DEAE cellulose as described by Denson (1967) .
ASSAYS FOR PROTHROMBIN, FACTOR VII, AND FACTOR X These were performed as described by Biggs and Macfarlane (1966) .
ANTIBODIES TO FACTOR VII AND FACTOR IX These were prepared as described by Denson (1967) by immunizing rabbits with the purified bovine clotting factors.
FACTOR IX INHIBITOR ASSAYS Different dilutions of plasma containing an inhibitor to factor IX were prepared in ordinary Christmas disease plasma. The dilutions were mixed with one-tenth volume of a concentrate containing factors II, VII, IX, and X, in which the factor IX concentration was 10 times that of normal plasma. The samples were then clotted in the presence of dilute brain extract and the residual factor IX was determined by the two-stage method (Biggs and Macfarlane, 1966) . A graph relating inhibitor concentration and residual factor IX is shown in Fig. 1 Table I shows that of 27 patients with Christmas disease whose plasma samples were tested using the one-stage prothrombin time and ox brain as thromboplastin only three gave a clearly prolonged clotting time. The defect would thus appear to be relatively uncommon. The three samples with markedly prolonged clotting times were tested freshly but the remaining samples were stored deep frozen and as a result might be expected to give the slightly prolonged prothrombin times which were obtained in some cases. The clotting times of all three abnormal plasma samples were shortened by the addition of normal plasma, but in mixtures of the abnormal samples one with another the clotting times remained prolonged. Although the addition of normal plasma shortened the clotting times of the abnormal samples, the clotting times were still longer than those of mixtures of normal plasma with absorbed normal plasma or factor VII-deficient plasma; this suggested the presence of some type of inhibitor rather than simple deficiency of a clotting factor. It can be seen from Table II (Biggs, Macfarlane, Denson, and Ash, 1965) and by brain extract and calcium in the presence or absence of factor VII (Denson, 1967) . The three patients' samples gave normal clotting times in the presence of Russell's viper venom and thus it was concluded that they contained nothing which inhibited or retarded the activation of factor X by Russell's viper venom. The effect of preformed intrinsic factor X activator on the samples was studied by incubating a mixture of factor IX, contact product, factor VIII, thrombin, and calcium chloride (Biggs et al., 1965) . This mixture gave the same clotting time when added with platelet substitute to either ordinary Christmas disease plasma or the patient's samples. Similarly preformed extrinsic factor X activator prepared by incubating factor X, factor VII, ox brain, and calcium chloride gave the same clotting times when subsampled into ordinary Christmas disease plasma or the abnormal samples. When factor VII was omitted and incubation mixtures consisted of factor X, ox brain, calcium chloride, and either normal or abnormal plasma added as a source of factor VII, the generation of factor Xa activity was slower in the presence of the abnormal plasma sample (Table  III) . The results of these experiments and previous ones indicated that the defect in the patients involved the activation of factor X by ox brain extract, but that the activation of prothrombin by preformed factor Xa occurred normally regardless of the method used for factor X activation. It thus seemed likely that the abnormal plasma contained an inhibitor for the reaction between ox brain thromboplastin, factor X, and factor VII. 0-2 ml factor X, 0-2 ml ox brain, 0-2 ml 0-025M calcium chloride, and 0-2 ml patient or normal plasma were incubated for timed intervals and 0-1 ml subsampled into 0-1 ml platelet substitute + 0-1 ml 0-025M calcium chloride. 0-1 ml of factor X-deficient substrate plasma was added and the clotting times recorded.
ASSAYS FOR FACTORS VII AND X Table IV shows that assays for both factor VII and factor X using human brain extract were within normal limits for all three patients. The curves in Fig. 2A show the effect on the clotting time of adding (a) different dilutions of normal plasma and (b) dilutions of one of the abnormal samples to factor VII-deficient plasma and testing the clotting times in the presence of ox brain. In the range of dilutions normally tested in assay procedures, between 1 in 10 and 1 in 100, the clotting times for the dilutions of the abnormal sample approximated the clotting times of the normal plasma dilutions. When dilutions between 1 in 1 and 1 in 10 were added, the clotting times of the abnormal sample dilutions were all much longer than the clotting times of the normal plasma dilutions. These curves again suggested the presence of an inhibitor in the normal sample to reactions between factor VII, factor X, and ox brain. Figure  2B shows the results of similar experiments performed using factor X-deficient plasma and it can be seen that the same general pattern of inhibition is obtained with the higher concentrations of the abnormal sample. One-stage prothrombin times were carried out on normal plasma and plasma from patient 3 using ox brain extract with the addition of different concentrations of ox factor VII or ox factor X and with varying concentrations of both factors. The results are shown in Fig. 3 and have been plotted by the Lineweaver-Burke method on the assumption that the clotting times are directly related to the reciprocal of the velocity of the reaction. The inhibitor appears to act competitively in a reaction involving both factors VII and X since at infinite concentration of both factors the inhibitory activity is eliminated.
NATURE AND ORIGIN OF THE INHIBITOR One characteristic feature of the ox brain thromboplastin inhibitor was that it was removed by adsorption of the plasma with aluminium hydroxide (see Tables II  and III) , and thus was associated with the fraction containing prothrombin, factor VII, factor IX, and factor X. A similar abnormal reaction to ox brain has not been described in Table V show that the prolonged one-stage clotting times using ox thromboplastin became normal when the patients' samples were treated with antisera or inhibitors to factor IX, but that the clotting times of normal plasma and ordinary Christmas disease plasma remained unchanged. Thus the constituent responsible for the abnormal reaction to ox brain is quantitatively removed by two different inhibitors to factor IX, and also by an antiserum to factor IX in all three patients.
Since the ox thromboplastin inhibitor was removed by the factor IX inhibitor samples it was reasonable to suppose that the factor IX inhibitor would be removed by the ox thromboplastin inhibitor in the patients' samples. An experiment was designed in which different dilutions of the two factor IX inhibitor samples were made in normal plasma, Christmas disease plasma, or plasma from patient 3. A factor IX concentrate was then added to these mixtures and the residual factor IX assayed by the two-stage method. The results appear in Table VI and show that as the proportion of normal plasma or plasma from patient 3 in the mixtures increases there is more residual factor IX and hence less inhibitor present.
It would therefore appear that these three patients have in place of normal factor IX an abnormal factor IX, which is functionally inactive but antigenically indistinguishable from normal factor IX. The inhibitor samples were diluted in normal plasma, Christmas disease plasma and plasma from patient 3. The dilutions were mixed with one-tenth volume of a concentrate containing factors II, VII, IX and X in which the factor IX concentration was 10 times that of normal plasma. The mixtures were then clotted in the presence of dilute brain extract and the residual factor IX was determined by the two-stage method (Biggs and Macfarlane, 1966) .
prepared from normal plasma, Christmas disease plasma, and the plasma from patient 3 (see Methods), and immunodiffusion plates (Ouchterloney, 1962) prepared in which different eluates were placed in the outer wells and an antiserum to factor IX in the centre wells. The results are shown in Fig. 4 , and indicate quite clearly fusion of the two precipitin lines in (a) and (b) between the factor IX antiserum and the eluates of normal plasma and the plasma of patient 3, suggesting antigenic identity of the two components. No precipitin lines were obtained with concentrates of plasma samples from 10 different patients with Christmas disease, some of which were placed in the remaining outer wells in (a)and(b). Precipitin lines were not obtained between the naturally occurring inhibitors to factor IX and eluates from normal plasma and plasma from patient 3, confirming the observations of previous workers (Hardisty, 1962, Colombani and Terrier, 1962) who were unable to demonstrate a precipitin reaction between normal plasma and inhibitors to factor IX.
MISCELLANEOUS CHARACTERISTICS OF THE INHIBITOR
The inhibitor was present in serum but absent from adsorbed plasma. (Denson, 1967) . Reversely the factor IX inhibitor was removed by the patients' samples but samples from patients with ordinary Christmas disease failed to neutralize the factor IX inhibitor. The abnormal factor IX protein also gave a precipitin line with a factor IX antibody which showed antigenic identity with the precipitin line of normal factor IX. Fantl, Sawers, and Marr (1956) It is suggested on the basis of the present work in which the presence of a protein antigenically indistinguishable from factor IX has been demonstrated in the plasma of three patients with Christmas disease, that Christmas disease might be classified into two types: haemophilia B+ (Christmas disease+) for the defect observed in these three patients who have an abnormal reaction to ox brain and whose blood contains a protein antigenically indistinguishable from factor IX, and haemophilia B-(Christmas disease-) for classical Christmas disease in which factor IX is absent. Strictly speaking 'factor IX deficiency' as a designation is applicable only to haemophilia B-. The test using ox brain thromboplastin, Two-Seven-Ten reagent, or Thrombotest is a simple means of distinguishing these two types of Christmas disease.
